All News
RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)
Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription..
Read Article
RAPID3 in Assessing Psoriatic Arthritis
My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.
Read Article
ICYMI: Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/9VbCJse6Tr
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: An Old Friend – Methotrexate in Psoriatic Arthritis
Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, particularly in the care of peripheral arthritis such as PsA.
https://t.co/kJdQ9Pd67v
#ACR21 @_Castillo_Pedro https://t.co/lpvZJaPcYd
Links:
Dr. John Cush RheumNow ( View Tweet)
Find all our #ACR21 podcast coverage here.
https://t.co/ZcWxysfoY1 https://t.co/mKOX4suJYi
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 at the #ACR21 meeting.
https://t.co/ZaXlhyEKwY
@drdavidliew @swethaann23 @MeralElRamahiMD @DrMiniDey @doctorRBC https://t.co/TNEJUEIRc4
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Emerging Therapies in Psoriatic Arthritis: Drs. Antoni Chan ( @synovialjoints) interviews Dr. FitzGerald about abstract #0490 and other PsA highlights being presented at the #ACR21 annual meeting.
https://t.co/1v8WhMkRHr https://t.co/UbqGkbupUM
Links:
Dr. John Cush RheumNow ( View Tweet)
This podcast is devoted to discussing patient satisfaction and factors important in their willingness or unwillingness (resistance) to change therapies.
https://t.co/QhjXkgW8f2 https://t.co/Zt8BxU0jVf
Links:
Dr. John Cush RheumNow ( View Tweet)
Geriatric Rheumatology:Improving care of aging patients
Dr.Kathryn Dao ( @KDAO2011) moderates a panel w/ Drs.Una Makris, Katherine Wysham, Sebastian Sattui + Devyani Misra, as they discuss aspects of improving care of/outcomes for aging patients. #ACR21
https://t.co/lF3yUZBEkd https://t.co/hYufA8ptqj
Links:
Dr. John Cush RheumNow ( View Tweet)
CBD and Opioids in Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) reviews abstract #1456 and #1777 presented at the #ACR21 annual meeting.
https://t.co/QnjgjZ13Uq https://t.co/PdbMmcCoIH
Links:
Dr. John Cush RheumNow ( View Tweet)
Frailty in Lupus: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0869 presented at the #ACR21 annual meeting.
https://t.co/5jR74VQBeG https://t.co/AJIhR5Waip
Links:
Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster and Rheumatoid Arthritis: Dr. Akhil Sood ( @AkhilSoodMD) reviews abstract #0981 presented at the #ACR21 annual meeting.
https://t.co/M95XQOBWVf https://t.co/X9vaAEAias
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety: Dr. Aurelie Najm ( @AurelieRheumo) interviews Dr. Choy about JAKi safety data, including abstracts #0958, #1940 and #1941 presented at the #ACR21 annual meeting.
https://t.co/yZnM9ttDYv https://t.co/eKrocRZdbl
Links:
Dr. John Cush RheumNow ( View Tweet)
Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meeting
https://t.co/00ojx9rXut https://t.co/bO9chTneoV
Links:
Dr. John Cush RheumNow ( View Tweet)
Redefining Aging
The American College of Rheumatology put together the Community Aging Hub and multiple sessions to help rheumatologists identify gaps in care for older patients with rheumatic diseases
https://t.co/9ciS6oDncK https://t.co/oPZrFU0dmQ
Links:
Dr. John Cush RheumNow ( View Tweet)
GLORIA Study - Is Prednisone Harmful in Elder RA?
The GLORIA study (ABST#1678) was a pragmatic, blinded placebo-controlled randomized trial where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.
https://t.co/eKXjiDpHlc https://t.co/JtCgc1uZnE
Links:
Dr. John Cush RheumNow ( View Tweet)
Osteoporosis in PsA: Dr. Rachel Tate ( @uptoTate) discusses Abstract #1325, presented at the #ACR21 annual meeting.
https://t.co/xnRkPnHeTr https://t.co/nE3ehhCB4j
Links:
Dr. John Cush RheumNow ( View Tweet)
Real Time Monitoring of Disease Activity? There's An App for That: Dr. Akhil Sood ( @AkhilSoodMD) discusses abstracts #0811 and #0373 presented at the #ACR21 annual meeting.
https://t.co/2qeZjhtMU4 https://t.co/MPCA3oox1U
Links:
Dr. John Cush RheumNow ( View Tweet)
Emerging Therapies in Psoriatic Arthritis: Drs. Antoni Chan ( @synovialjoints) interviews Dr. FitzGerald about abstract #0490 and other PsA highlights being presented at the #ACR21 annual meeting.
https://t.co/WVgcE8TVpZ https://t.co/1uOafjFWPg
Links:
Dr. John Cush RheumNow ( View Tweet)
RAPID3 in Psoriatic Arthritis: Dr. Meral El Ramahi ( @MeralElRamahiMD) reports on abstract #0633 presented at the #ACR21 annual meeting.
https://t.co/DO7YXhD3YA https://t.co/vcegdPx8OL
Links:
Dr. John Cush RheumNow ( View Tweet)